MAPT and Mental deterioration: The study participants who are CH with pathological CSF Aβ42/tau have been recently confirmed to be at higher risk for a cognitive decline when we found 11/28 (40%, p < 0.0001) of this CH-PAT group declined cognitively with an AD pattern after 4 years, while none of the CH-NAT group had measurable decline (Harrington et al., 2019).